BrainStorm Appoints Haro Hartounian as COO
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
Express News | Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.d. as Chief Operating Officer
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the...
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersCalidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:E
Brainstorm Cell Therapeutics (BCLI) Rockets in Afterhours Despite Questions Raised
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) experienced a lackluster Friday, with a slight dip of approximately 0.5%. However, after the closing bell, the stock surged dramatically during the afterhours session, soaring by nearly 20% within a matter of hours. This significant afterhours movement has left many market observers puzzled, as there seems to be no ...
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDA
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment With NurOwn
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn®).
Brainstorm Cell Therapeutics | 10-Q: Quarterly report
Express News | Brainstorm Cell Q1 2024 Adj EPS $(0.05) Beats $(0.07) Estimate
Express News | Brainstorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Express News | Brainstorm Cell Therapeutics Shares Are Trading Lower After the Company Announced It Received a Letter From the Nasdaq Indicating That It Did Not Regain Compliance With the Minimum Bid Price Requirement
Express News | Brainstorm Cell Therapeutics: Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement by April 29
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u
Brainstorm Cell Therapeutics Executive Leadership Changes
BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer
Express News | Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited clinical trial. The New York-based company,
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
Express News | Brainstorm Cell Therapeutics Inc - Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
No Data